Albendazole + IvermectinThird Party Manufacturing in India

Albendazole and Ivermectin work synergistically to provide comprehensive broad-spectrum antiparasitic coverage.

Albendazole binds to parasite tubulin, inhibiting microtubule formation and glucose uptake, which starves the parasite of energy. Ivermectin amplifies this by binding to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, causing hyperpolarization, paralysis, and death of the parasite.

Unlike monotherapy, the combination of Albendazole and Ivermectin offers superior efficacy in eradicating mixed parasitic infections and resistant strains. It is highly effective and well-tolerated for patients requiring robust deworming and treatment of filariasis or scabies.

Therapeutic Uses

Albendazole + Ivermectin is prescribed for the treatment of:

• Lymphatic Filariasis: Used in mass drug administration programs to halt the transmission of the disease.
• Mixed Helminth Infections: Effective against concurrent intestinal nematode and ectoparasite infections.
• Resistant Scabies: Provides internal systemic treatment for severe or crusted scabies.
• Strongyloidiasis: Eradicates threadworm infections efficiently.

Why Manufacturers Choose Albendazole + Ivermectin

The synergistic action of this combination has made it increasingly popular in public health programs and routine clinical practice in endemic regions. It simplifies dosing regimens for patients and ensures higher compliance rates.

This makes the Albendazole + Ivermectin combination one of the most sought-after products for third party manufacturing in India, with consistent demand from PCD franchise operators and export markets targeting tropical diseases.